dataesr/scientific-paragraphs-categorization huggingface dataset:
Acknowledgements. This research was enabled in part by  West Grid  (www. westgrid. ca) and  Compute Canada  (www. computecanada. ca). Financial support was provided by the  Natural Sciences and Engineering Research Council of Canada ,  Polar Continental Shelf Program  and  Simon Fraser University. Field data were collected with permission and support from  Kluane  and  White River First Nations, Parks Canada  and  Yukon Government. Mass-balance model output was provided by  Erik Young. SPOT7 data were obtained thanks to public funds received in the framework of  GEOSUD , a project ( ANR-10-EQPX-20 ) of the programme ' Investissements d'Avenir ' managed by the  French National Research Agency. EB acknowledges support from the  French Space Agency (CNES)  through the  TOSCA  and  DINAMIS  projects.
Meniscal lesions in skeletally immature patients can lead to joint degradation and knee instability. Meniscal allograft transplant (MAT) surgery is a solution to maintain knee stability. There is a lack of consensus on MAT surgery outcomes in pediatric patients. A systematic review was conducted according to the PRISMA guidelines. PubMed, Scopus and EMBASE databases were searched from 1965 to June 2022. Studies were evaluated using the Newcastle-Ottawa Scale (NOS). Three studies were selected, and 58 patients were included (mean age 15. 9 years) in total. The lateral meniscus was involved in 82. 8% of all MAT surgeries. Post-meniscectomy syndrome and discoid meniscus were the main indications for MAT surgery. All studies reported improved subjective clinical scores and levels of sport after the surgery.
Eligibility Criteria and Search Strategy Original, full-text published studies in English were considered for inclusion if they investigated meniscal allograft transplantation and reported clinical outcomes in chil-dren and adolescents (<18 years old). No peer-reviewed articles, letters or editorials were excluded. A literature search was conducted from 1965 to April 2023 in the PubMed/Medline (National Library of Medicine, Washington, DC, USA), Scopus and EMBASE databases using the following combination of keywords; (i) "meniscal" AND "transplant" AND "children"; (ii) "meniscal transplantation" AND "adolescent" (iii) "meniscal transplantation" AND "pediatric", (iv) "meniscectomy" AND "pediatric", (v) "meniscal transplantation" AND "skeletally immature patient". No specific fields were designated in the search engines for the keywords  [14].
Study Selection The initial literature search yielded 934 records. After removing duplicate records and applying the publication year range, 531 studies were considered for screening. After excluding studies according to the inclusion criteria, i. e. , language (n = 26), title (n = 365) and abstract (n = 84), 46 studies were assessed for inclusion via full-text reading. Fourteen studies were excluded for article type, and twenty-nine were not included due to the study participant age range. In total, three studies  [16] [17] [18]  were included and processed for data extraction. Figure  1.
| MATERIALS AND METHODS A total of 10,896 donation samples collected between the 19th and 24th August, 2022 were analyzed in the study. These were combined to 454 minipools by NHBT for routine HIV and hepatitis B, C and E virus nucleic acid testing (NAT), each comprising 24 blood or platelet donation samples. Extraction of donor demographic data was performed by NHS Blood and Transplant (Table  S1 ; Suppl. Data). A pre-quantified MPXV DNA standard was provided by the National Institute of Standards and Technology (NIST), United States. Serial dilutions were made in the supplied dilution buffer and subsequently in RNA buffer solution (1 mM sodium citrate, pH 6. 4 supplemented with 50 ng/μl of herring sperm DNA and 0. 14 units/μl RNAsin (Thermofisher) for larger scale limiting dilution assays).
Ethics approval and informed consent. The SAPRIS-SERO study (registered #NCT04392388) was conducted in accordance with the relevant guidelines and regulations and was approved by the ethics committee CPP Sud-Méditerranée III on April 27th 2020 and by the CNIL #920,193. All participants provided written or electronic informed consent for participation in each cohort and a specific electronic informed consent for participation in the SAPRIS-SERO study.
Discussion In this study, we used seroprevalence data obtained from screening a large population-based sample from 3 French prospective cohorts to assess the associations between ABO blood types and the risk of SARS-CoV-2 infection. Our results showed a decreased seroprevalence of anti-SARS-CoV-2 antibodies in type O individuals compared to all others. Among non-O blood types, types A and AB were more likely positive for SARS-CoV-2 infection. No association was observed with type B or RhD types. These results confirmed prior observations obtained in other population settings, namely a decrease risk of infection for type O individuals and an increase risk for type A individuals, with some indication of increased risk for type AB individuals as well, thus strengthening the evidence towards a differential susceptibility of SARS-CoV-2 infection according to ABO blood types.
Yet, most studies so far involved registry or hospital data of SARS-CoV-2 positivity from PCR test results in patients or blood donors in comparison to the general population  [8] [9] [10]  and fewer studies used seroprevalence data, mostly in small samples, with the exception of a recent report in 32,600 blood donors  11. In turn, our study used seroprevalence data and a screening design whereby a large population-based sample of 67,340 participants involved in the SAPRIS-SERO project received a dried blood spot sampling kit. This allowed us to test for SARS-CoV-2 infection in a single general population, regardless whether the participants sought testing or had symptoms, allowing detecting a large panel of infected cases. This differential susceptibility to SARS-CoV-2 infection according to blood types could be due to the incorporation of ABH antigens on the envelop of SARS-CoV-2 virions, leading to a likelihood of infection from one individual to another following ABO incompatibility  9, 10.
However, we did not have access to racial and ethnic data as the collection of such data is generally not permitted in the framework of French cohort studies. Finally, our data only reflect infections occurring before November 2020, that is, before the emergence of variants but also before the large-scale vaccination campaigns. To conclude, this study adds to the current body of evidence providing data on the association between ABO blood types and the risk of SARS-CoV-2 infection from screening a large sample from the general population using seroprevalence data. Our results confirmed a higher susceptibility of infection for individuals of blood types A and AB and a lesser risk for blood type O, thereby providing additional insights into the dynamic of SARS-CoV-2 infection. However, considering the magnitude of association and the current mechanistic hypotheses related to blood type incompatibility (hence a collective rather than individual type of protection), type O individuals are not without risk of infection and protective measures remain the best way of preventing SARS-CoV-2 transmission and infection.
Acknowledgements The authors warmly thank all the volunteers of the Constances,  E3N-E4N  and  NutriNet-Santé  cohorts for their continuous participation in the study and for participating in the  SAPRIS-SERO  project. We thank the  CEPH-Biobank  staff for their adaptability and the quality of their work. In the virology department, we thank  Dr Nadège Brisbarre  and the technical staff for impeccable management of samples and serological assays.
Funding The  SAPRIS/SAPRIS-SERO  projects received funding from  ANR  ( Agence Nationale de la Recherche , # ANR-20-COVI-000 , # ANR-10-COHO-06 ),  Fondation pour la Recherche Médicale  (# 20RR052-00 ), and  Inserm  ( Institut National de la Santé et de la Recherche Médicale , # C20-26 ). The  NutriNet-Santé cohort study  was supported by the following public institutions:  Ministère de la Santé ,  Santé Publique France ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Institut National de Recherche pour l' Agriculture, l' Alimentation et l'Environnement (INRAE) ,  Conservatoire National des Arts et Métiers  (CNAM) and  Université Sorbonne Paris Nord. The CONSTANCES cohort benefits from grant  ANR-11-INBS-0002  from the  French National Research Agency. CONSTANCES is supported by the  Caisse Nationale d' Assurance Maladie , the  French Ministry of Health , the  Ministry of Research , and the  Institut National de la Santé et de la Recherche Médicale (INSERM).
CONSTANCES is also partly funded by  AstraZeneca ,  Lundbeck ,  L'Oréal , and  Merck Sharp & Dohme Corp. The  E3N-E4N  cohort is supported by the following institutions:  Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation, INSERM, University Paris-Saclay, Gustave Roussy , the  MGEN , and the  French League Against Cancer. Study investigators are independent from the funders. Funders had no role in the study design, the collection, analysis, and interpretation of data, the writing of the manuscript, or the decision to submit the article for publication.
Data availability Data from the study are protected under the protection of health data regulation set by the French National Commission on Informatics and Liberty (Commission Nationale de l'Informatique et des Libertés, CNIL). The data can be made available upon reasonable request to the corresponding author (m. deschasaux@eren. smbh. univ-paris13. fr), after a consultation with the steering committee of the SAPRIS-SERO study. The French law forbids us to provide free access to SAPRIS-SERO data; access could however be given by the steering committee after legal verification of the use of the data. Please, feel free to come back to us should you have any additional question.
A ≥4-point WI-NRS reduction at week 24 in the dupilumab and placebo arms was achieved by 60. 0% and 18. 4% of patients, respectively, in PRIME (95% confidence interval (CI), 27. 8-57. 7 for the difference, P < 0. 001) and at week 12 by 37. 2% and 22. 0% of patients, respectively, in PRIME2 (95% CI, 2. 3-31. 2; P = 0. 022). Dupilumab demonstrated clinically meaningful and statistically significant improvements in itch and skin lesions versus placebo in PN. Safety was consistent with the known dupilumab safety profile. ClinicalTrials. gov identifiers: NCT04183335 and NCT04202679. Prurigo nodularis (PN), a chronic inflammatory skin condition characterized by intensely pruritic papulonodular lesions, substantially impacts quality of life (QoL) 1,2. Variable prevalence was reported in several countries  [3] [4] [5] [6]  ; in the United States, it affects annually an estimated 18-72 adults per 100,000 population  7, 8.
Online content Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi. org/10. 1038/s41591-023-02320-9. University of Miami, Miami, FL, USA. 2  Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3  University Hospital Münster, Mϋnster, Germany. 4  Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5  Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Study design PRIME and PRIME2 were phase 3, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week trials designed to evaluate efficacy and safety of dupilumab in adults with PN inadequately controlled with topical prescription therapies. Patients were enrolled in 16 countries in North and South America, Europe and Asia, from 12 December 2019 to 3 February 2022 (PRIME) and 16 January 2020 to 22 November 2021 (PRIME2). Each study had a 2-4-week screening period, followed by a 24-week intervention period and a 12-week post-treatment follow-up period (Extended Data Fig. 1 ). The PRIME and PRIME2 protocols were developed by the sponsors, Sanofi and Regeneron Pharmaceuticals Inc. (redacted protocols are provided in Supplementary Data 1). Data were collected by the investigators and analyzed by the sponsors.
Acknowledgements This research was sponsored by  Sanofi  and  Regeneron Pharmaceuticals Inc. ClinicalTrials. govidentifiers:  NCT04183335  and  NCT04202679. The authors thank the patients for their participation in these studies and  S. Colucci  of  Sanofi  and  L. Williams  of  Regeneron Pharmaceuticals Inc. , for their contributions. Medical writing/editorial assistance was provided by  M. Coimbra  and  I. Oprea  of  Excerpta Medica  and was funded by  Sanofi and Regeneron Pharmaceuticals Inc. , according to the  Good Publication Practice guideline. A full list of investigators is provided in the Supplementary Information.
ACKNOWLEDGMENTS This manuscript and the  ESOT Consensus Workgroup  is a collaborative work product of ESOT and its Sections and Committees. We would like to thank  Devi Mey ,  Justyna Klimek ,  Irene Garcia ,  Giovanna Rossi ,  Daniele Roppolo  and the entire ESOT staff for their tireless efforts to support this endeavor. The authors also thank  Liset Pengel  and her coworkers at the  Centre for Evidence in Transplantation , who provided the literature list based upon our drafted PICOs.
pneumoniae, received either usual care or usual care + probiotic treatment for 14 days  (Nouvenne et al. , 2015). Loss of the CRE K. pneumoniae of stool samples was observed in 10 patients receiving probiotics versus 2 patients in the control group. Although these results seems promising, no data are available regarding the composition of the commercial symbiotic treatment used, nor about the kinetic of decolonization of the samples. In a more recent fundamental study, Klebsiella oxytoca was shown to outcompete carbapenemase producing K. pneumoniae strains in a murine model  (Osbelt et al. , 2021). In this work, mice were co-colonized or pre-colonized with K. oxytoca before colonization with a carbapenem resistant K. pneumoniae strain. Elimination of carbapenem resistant K. pneumoniae was successfully completed in 80% of the mice after 42 days, versus 20% of the control group.
Data availability: The main simulation data generated during this study are available at (https://osf. io/f69ns/) with a permanent DOI 10. 17605/OSF. IO/F69NS. Aura MLS v4 data is available at https://disc. gsfc. nasa. gov/datasets?page=1&keywords=AURA%20MLS. Water vapor radiosonde data is available at https://doi. org/10. 5065/p328-z959 (26).
Acknowledgements The authors are grateful to The  Ministry of Education, Culture, Research and Technology of Indonesia  for supporting this study through the Letter of Agreement of Implementation with Research Grant No  3552/IT3. L1/PT. 01. 03/P/B/2022  dated  May 31 , 2022. The authors are grateful to  Salsabila Putri Permana ,  Hizbulloh Almuzahiq , and  Tatang  for their assistance during the study.
Study Searching Protocol We performed a review of current literature by analysing PubMed, Scopus and Web of Science electronic databases of the last 20 years of literature (from April 2001, to April 2022) by two different authors. Keywords used for the study research were: "Oropharynx carcinoma" and/or "oropharyngeal squamous cell carcinomas" and/or "TORS and Oropharynx" and/or "oropharyngeal squamous cell carcinomas treatment". The investigators examined titles and abstracts of papers available in English.
Acknowledgements This research was partially supported by the  French Agence Nationale de la Recherche  through the  ANR   MUPHTA  project under Grant  ANR-20-CE24-0016. Additionally, the  Hauts-de-France Regional (HdF) Council  provided support through the  eLIFT  project. The authors also acknowledge the financial assistance from the  European Regional Development Fund (ERDF)  and the  I-SITE UNLE. Furthermore, this work  M. Bsaibes ,  Y. Quiquempois ,  M. Bigot  et al. was carried out within the framework of the  Contrat de Plan Etat-Region (CPER WaveTech) , which is supported by the  Ministry of Higher Education and Research , the  HdF Regional council , the  Lille European Metropolis (MEL) , the  Institute of Physics of the French National Centre for Scientific Research (CNRS)  and the  ERDF.
Data sources We searched for published and unpublished national estimates of RSV-associated hospitalisations (defined as any admission that contained at least one respiratory infectionspecific ICD-10 code at any point during admission) in children under 5 years in EU countries that were calculated using regression models as input data for the statistical analysis. The EU was chosen as the preferred region as it is a highly integrated political and economic union of 28 member states, making it a more homogeneous and consistent entity than Europe as a whole.
RSV-associated hospitalisation estimates from the RESCEU project The data sources for Denmark, England, Finland, Norway, the Netherlands, and Scotland have been described in papers that were previously published by the REspiratory Syncytial virus Consortium in EUrope (RESCEU)  [3, 7]. A retrospective study of overall respiratory hospital admissions (i. e. , respiratory tract infections with or without an associated pathogen), RSVrelated respiratory admissions, and other pathogen-respiratory admissions in children <5 years of age using routinely collected hospital admissions databases was conducted by Reeves and colleagues in these 6 countries of the EU/European Economic Area (EEA)  [3]. These data were then used by Johannesen and colleagues to calculate age-specific estimates of RSV-associated hospitalisations in children during 2006-2018 in these countries using a linear regression approach, with estimates available for the following age groups: 0-2, 3-5, 6-11, 12-35, and 36-59 months  [7].
The same search string as the systematic review conducted by Li and colleagues was used  [2]  (see Supplementary material); MEDLINE and EMBASE databases were searched from 1 st January 2019 to 30 th November 2021 for original articles. Papers published before 2019 that had been included by Li and colleagues were added to the reference list of relevant papers and further assessed for eligibility. No language restrictions were applied as long as an English abstract was available to decide on eligibility. To be included, a study had to report (i) national estimates of RSV-associated hospitalisations in children in EU countries calculated by using linear regression models (this criterion was chosen in order to have a homogeneous pool of estimates for the EU  [9] ) (ii) details (i. e. , ICD codes) on the diagnosis (i.
e. , bronchiolitis, lower respiratory infections, etc. ), and (iii) analyse the same age bands used by Johannesen and colleagues  [7]. After removing duplicates, titles and abstracts were independently screened by two researchers (MDR and ROY) and the articles that were not excluded were retrieved in full copy and independently read by two authors (MDR and ROY). The papers that had been included in the previous systematic review were further assessed for eligibility, and the reference list of all eligible papers was checked by means of backward citation chaining for further relevant references. Data extraction was organised using an internally piloted spreadsheet  [2]. The estimates reported by the included articles were then extracted and used as input data for the statistical modelling, along with other information (data sources, details on the primary diagnosis, years in which the study was conducted, etc.
Statistical Analysis A two stage-modelling approach was used to estimate the RSV-associated hospitalisations and rates in the EU in children under 5 years old. This method was adapted from prior work focused on influenza-associated mortality during the 2009 pandemic  [9]  and for seasonal influenza  [10]. Since the period covered by the eligible studies was 2006-2018, the United Kingdom (UK) was included in the EU estimates. In Stage 1, we identified annual age-specific estimates of RSV-associated hospitalisations from respiratory causes that were calculated using regression models. Data from the six RESCEU countries, plus those which were found in the literature and matched the inclusion criteria (see Results), were used as input data for Stage 2. In Stage 2, we used the country estimates to extrapolate the hospitalisation burden and generate plausible values for all EU countries using two different modelling approaches, each involving two steps: (1) a data creation step using the matching approach or the multiple imputation approach, and (2) a data analysis step where a hierarchical linear random effects model is used to project the burden in all EU countries.
For both approaches, the data creation step relied on 10 country-specific indicators representing health conditions at a demographic, geographic and population level (see Supplementary material)  [9]. As two different sets of 10 indicators were used, the statistical modelling produced 4 sets of results (see Supplementary material), each related to the combination of one set of indicators and one modelling approach. An average of the four different models was calculated and used to calculate the absolute annual number and rates of RSV-associated hospitalisations (with uncertainty intervals) by country for the following age groups: 0-2, 3-5, 6-11, 12-35, and 36-59 months, which are consistent with the previously published age groups used by Johannesen and colleagues  [7]. We also assessed the hospitalisations rate for the EU in children aged 0-59 months and calculated the ratio of hospitalisations that occurred in each age group, considering our estimated total number of RSV-associated hospitalisations as denominator.
g. types) over the years. Our study found substantial variation in the hospitalisation rates across the EU, but we did not explore these differences as this would require more advanced analysis methods which would include factors such as the circulation of other respiratory viruses (e. g. , influenza and SARS-CoV-2), healthcare (indicators related to access and quality of healthcare or differences in the clinical practice), climatic and environmental factors  [32] [33]. We also used two sets of ten indicators to produce the extrapolations (see Supplementary material): these sets were chosen based on the availability of data in all included countries (e. g. , Scotland and England for the UK) and are not always specific to RSV. From a statistical perspective, this point is not likely to influence the estimates (as the indicators only aim to capture variability across countries), but it would be more elegant to develop indicator sets that are better aligned with RSV, as was done for influenza  [9].
Methods An observational cadaver study was performed to collect data on immediate fixation performance and safety as reflected by: 1. Correct anchor placement identified by palpation and then dissection 2. Distance between anchors and vulnerable structures in the pelvic cavity 3. The pull-out forces required to pull the anchor elements The researchers determined that studying four samples would be enough to answer the research questions. As no living subjects were evaluated in this study, there was no need to obtain approval of an ethics committee. The data on continuous variables with normal distribution were presented as mean ± SD and compared in study groups using Student's t test. One-sided p value of < 0. 05 was considered significant.